Guideline update
NCCN adds Lifyorli plus nab‑paclitaxel as a preferred option in ovarian cancer
Following FDA approval in March 2026 of Lifyorli (relacorilant) plus nab‑paclitaxel, NCCN has added the combination as a preferred regimen for patients with platinum‑resistant ovarian cancer who've received up to three prior lines of therapy, including bevacizumab. The guideline update reflects expert consensus based on phase 3 ROSELLA results, published in The Lancet, demonstrating a clinically meaningful overall survival benefit.
An NCCN footnote also specifies that steroid premedication should not be used with this regimen, an important administration consideration for clinical practice.
Source: National Comprehensive Cancer Network. (2026). NCCN clinical practice guidelines in oncology: Ovarian cancer (Version 4.2026).